Company
BerryBio was founded in February 2021. It is a venture-backed biotechnology startup committed to advancing the research and clinical development of targeted protein degradation (TPD). The company is headquartered in Shanghai, China, with offices in the United States. BerryBio was co-founded by scientists in the field of protein degradation, experienced clinical translational experts, and entrepreneurs familiar with the capital market. The core objective of BerryBio is to develop innovative drugs that focus on targetdifferentiation and unmet clinical needs. Our research and development projects encompass PROTAC (bi-functional small molecule intracellular protein degradation technology), smLYTAC (bi-functional small molecule targeted lysosomal degradation of extracellular and cell membranes proteins), and Molecular Glue (a targeted degradation technology based on innovative monovalent small moleclues). BerryBio currently has several pipelines under development, primarily focusing on the field of oncology.
Description
A biotech focused on protein degradation technology
